The T2Carba Resistance+™ Panel detects gram-negative carbapenem-resistance genes direct from whole blood in 3 to 5 hours. It is expected to be available for research use only during the first half of 2019. T2Carba Resistance+ has been developed through a partnership with Allergan and CARB-X. T2 Biosystems owns exclusive worldwide distribution rights to the T2Carba Resistance+ Panel.
Rapid detection of gram-negative resistance markers: The T2Carba Resistance+ Panel includes the detection of Enterobacter and Klebsiella spp. as well as common resistance markers. The Panel utilizes the same T2Dx® Instrument as the T2Bacteria® and T2Candida® Panels – the first and only FDA-cleared panels for direct detection of sepsis-causing bloodstream infections.
The growing threat of gram-negative carbapenem-resistant bloodstream infections: The increased prevalence of multidrug-resistant organisms is recognized as a serious threat to public health. Current diagnostics are ill-equipped to deal with the current multidrug-resistant organisms and they require a positive blood culture–which takes 1 to 5 or more days–before subculture and antimicrobial susceptibility testing (AST) or genomic testing can be performed. It is expected that drug-resistant organisms will continue to increase thus reducing the effectiveness of last-line antibiotics if current diagnostic tools and empiric therapy remain the same.
Accelerated identification to combat antibiotic resistance: Direct-from-blood rapid diagnostics have the potential to prevent the spread of multidrug-resistant organisms and improve patient outcomes by enabling rapid identification of the genes and species associated with antibiotic resistance. In addition, these tests could be used to accelerate clinical trials for new antibiotics and increase the time to commercial availability.
Contact us to learn more about T2Carba Resistance+!